AstraZeneca gets regulatory green light for breast cancer drug
Faslodex can now be deployed as a single therapy following regulatory sign off
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 41 of 55
Champions Oncology hooks up with AstraZeneca to work on characterising tumour models
The collaboration will help Astra develop further therapeutic approaches for patients
AstraZeneca ovarian cancer drug approved for wider use
Lynparza was initially approved to be given to women with advanced ovarian cancer who had stopped responding to three rounds of chemotherapy
FTSE 100 plunges on North Korea fears
The FTSE 100 finished 108 points lower at 7,390, about 13 points above its intra-day low
AstraZeneca scores much-needed clinical success
It has been granted a priority review by the US Food & Drug Administration for acalabrutinib, which has been developed to treat a rare form of non-Hodgkin’s lymphoma
AstraZeneca on the front foot after US FDA speeds up process for Imfinzi lung cancer drug
AstraZeneca is making progress on its lung cancer drug Imfinzi but suffered a set back on its Mystic treatment
AstraZeneca's share price slump on Mystic trial unwarranted, says investor Neil Woodford
AstraZeneca has maintained that its Mystic lung cancer treatment could be positive on improving overall survival rates after a failed trial
Merck & Co cuts full year profit guidance; agrees drug collaboration with AstraZeneca
Merck & Co is yet to determine the full impact of the ‘Petya’ cyber attack in June that disrupted operations
FTSE 100 fagged out as US Food and Drug Administration targets nicotine levels in cigarettes
Despite the beating meted out to IMPs and BATs, the Footsie rallied in the last half hour to trim its heavy losses
Diageo - Up 7% and trading ahead of expectations, but still being whupped by its rivals
Liberum’s price target is £20 a share, which is £4.32 below the current price
AstraZeneca – long road back for toxic drug giant
There was a lot of hope and expectation factored into the share price ahead of the findings with AZ up 20% from January
Billions wiped off AstraZeneca’s value as key lung cancer study fails to meet primary endpoint
It had been hoped that the combination of two of its lead immuno-oncology compounds, Imfinzi and tremelimumab, would lead the drugmaker into a new era
Archive
FTSE 100 closes nine points lower as AstraZeneca weighs
It's been a busy day here in London; 15% of FTSE 100-listed companies have had some sort of meaningful news out...
Archive
Lloyds to report strong quarterly figures in first results since government sold remaining stake
Lloyds Banking Group and Royal Dutch Shell are among a slew of companies reporting earnings on Thursday
Archive
Lloyds and Barclays to dominate manic week of corporate earnings
Week ahead: Lloyds, Barclays, AstraZeneca, GlaxoSmithKline, Sky, Reckitt Benckiser
FTSE 100 ends lower but European shares fare worse
London stocks were on the front foot this morning, but they quickly retreated this afternoon...
Archive
Rookie Investor: If you’re under 40, why haven’t you opened a Lifetime ISA?
Of course if you’ve already done so, this article probably doesn’t apply to you…
FTSE 100 fades despite demand for miners
The Footsie closed down on the day but up on the week
AstraZeneca plummets on reports that CEO Pascal Soriot is set to join Israeli competitor Teva
Financial news website Calcalist has reported that Soriot is close to being unveiled as Teva’s new boss
Investments and investor services
FTSE 100 closes down a shade with BT Group plc top dog
Footsie was becalmed throughout the day, leaving the mid-cap FTSE 250 to claim the limelight